Consensus Codexis, Inc.

Stocks

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 30/10/2026 +04			5-day change	1st Jan Change
1.220 ^USD	-3.17%		-6.87%	-25.15%

10-22	Certain Warrants of Codexis, Inc. are subject to a Lock-Up Agreement Ending on 22-OCT-2026.	CI
10-22	Certain Restricted Stock Units of Codexis, Inc. are subject to a Lock-Up Agreement Ending on 22-OCT-2026.	CI

Evolution of the Average Target: Codexis, Inc.

Evolution of the Target Price: Codexis, Inc.

Changes in Analyst Recommendations: Codexis, Inc.

9cc624edf981a7ea63efba1.ti67uZNNAV_RGxCi5xp34TzF7QbVxUlfcoHirSEb9o4.8V3Jysd4dwC0WnPptzc5rFGrrkKstAxpMO7U4hFducXARe7-wDh7Kporcw~0866fb2a73eea4aca8200ee0c63e820d

Analysts' recommendations: Codexis, Inc.

19/08/24	Benchmark Capital Downgrades Codexis to Hold From Buy	MT
30/05/24	Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target	MT
29/02/24	Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9	MT
07/11/23	Benchmark Downgrades Codexis to Hold From Buy	MT
06/11/23	Piper Sandler Trims Price Target on Codexis to $10 From $14, Maintains Overweight Rating	MT
14/08/23	Stifel Adjusts Price Target on Codexis to $5 From $9, Maintains Buy Rating	MT
09/05/23	Benchmark Adjusts Price Target on Codexis to $9 From $15, Keeps Buy Rating	MT
09/05/23	HC Wainwright Downgrades Codexis to Neutral From Buy	MT
27/02/23	HC Wainwright Adjusts Price Target on Codexis to $9 From $15, Keeps Buy Rating	MT
19/01/23	Piper Sandler Adjusts Price Target on Codexis to $23 From $22, Maintains Overweight Rating	MT
07/11/22	HC Wainwright Adjusts Price Target on Codexis to $15 From $25, Maintains Buy Rating	MT
08/08/22	HC Wainwright Adjusts Codexis' Price Target to $25 From $27, Reiterates Buy Rating	MT
18/07/22	HC Wainwright Adjusts Codexis' Price Target to $27 from $38, Keeps Buy Rating	MT
15/07/22	Cowen & Co Adjusts Codexis Price Target to $21 From $39, Maintains Outperform Rating	MT
15/07/22	Piper Sandler Adjusts Codexis' Price Target to $22 From $35, Reiterates Overweight Rating	MT
05/11/21	HC Wainwright Adjusts Price Target on Codexis to $38 From $33, Maintains Buy Rating	MT
15/10/21	Codexis : HC Wainwright Adjusts Codexis' Price Target to $33 from $28, Keeps Buy Rating	MT
06/08/21	Codexis : Piper Sandler Adjusts Codexis' Price Target to $34 From $32, Maintains Overweight Rating	MT
18/06/21	Codexis : HC Wainwright Adjusts Codexis' Price Target to $27 From $26, Keeps Buy Rating	MT
12/04/21	Codexis : Piper Sandler Starts Codexis at Overweight With $32 Price Target	MT
01/03/21	Codexis : Stifel Starts Codexis at Buy with $30 Price Target	MT
26/02/21	Codexis : HC Wainwright Adjusts Codexis' Price Target to $26 From $21, Maintains Buy Rating	MT
30/12/20	Codexis : Benchmark Capital Adjusts Codexis PT to $29 From $21, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CODEXIS, INC.					+387.53%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+58.62%
	Weighted average by Cap.					+22.84%